Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Vigabatrin
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Bora Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Acquisition
Bora Expands Rare Disease Portfolio with Pyros Pharma Acquisition
Details : Through the acquisition of US-based Pyros, Bora will expand his pipelines by adding some candidates such as Vigafyde (vigabatrin), which is indicated for the treatment of infantile spasms.
Product Name : Vigafyde
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 25, 2024
Lead Product(s) : Vigabatrin
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Bora Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Vigabatrin
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Pyros Pharmaceuticals: FDA Approves VIGAFYDE as Ready-to-Use Oral Solution
Details : Vigafyde (vigabatrin) is approved as monotherapy for pediatric patients with refractory complex partial seizures or infantile spasms in patients 1 month to 2 years of age.
Product Name : Vigafyde
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 17, 2024
Lead Product(s) : Vigabatrin
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vigabatrin
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Pyros Pharmaceuticals Reports Positive Outcome in European Procedure for VIGZIP™ Approval
Details : Vigzip (vigabatrin) is a Gamma-amino-N-butyrate transaminase inhibitor, which is indicated for the treatment of patients with infantile spasms (West's syndrome).
Product Name : Vigafyde
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 15, 2024
Lead Product(s) : Vigabatrin
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable